 Mary Hayden
Concepts (376)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 36 | 2018 | 262 | 7.160 |
Why?
| | beta-Lactamases | 22 | 2018 | 64 | 5.480 |
Why?
| | Klebsiella pneumoniae | 15 | 2018 | 50 | 4.770 |
Why?
| | Bacterial Proteins | 22 | 2017 | 78 | 4.550 |
Why?
| | Klebsiella Infections | 15 | 2018 | 48 | 3.670 |
Why?
| | Chlorhexidine | 15 | 2019 | 50 | 3.630 |
Why?
| | Anti-Bacterial Agents | 31 | 2019 | 374 | 3.570 |
Why?
| | Gram-Positive Bacterial Infections | 20 | 2014 | 63 | 3.510 |
Why?
| | Vancomycin Resistance | 12 | 2014 | 33 | 3.400 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 15 | 2019 | 82 | 3.350 |
Why?
| | Infection Control | 22 | 2019 | 143 | 3.280 |
Why?
| | Enterococcus | 21 | 2014 | 65 | 3.090 |
Why?
| | Carrier State | 17 | 2019 | 55 | 2.560 |
Why?
| | Enterobacteriaceae | 6 | 2016 | 34 | 2.520 |
Why?
| | Bacteremia | 18 | 2019 | 110 | 2.410 |
Why?
| | Staphylococcal Infections | 17 | 2019 | 148 | 2.350 |
Why?
| | Intensive Care Units | 23 | 2019 | 245 | 2.210 |
Why?
| | Disease Outbreaks | 13 | 2017 | 88 | 2.140 |
Why?
| | Enterobacteriaceae Infections | 6 | 2018 | 35 | 2.100 |
Why?
| | Anti-Infective Agents, Local | 10 | 2019 | 49 | 2.010 |
Why?
| | Baths | 8 | 2019 | 26 | 1.940 |
Why?
| | Drug Resistance, Multiple, Bacterial | 7 | 2019 | 33 | 1.650 |
Why?
| | Drug Resistance, Bacterial | 8 | 2018 | 53 | 1.610 |
Why?
| | Housekeeping, Hospital | 3 | 2014 | 6 | 1.480 |
Why?
| | Escherichia coli | 4 | 2018 | 67 | 1.440 |
Why?
| | Carbapenems | 6 | 2018 | 27 | 1.420 |
Why?
| | Humans | 98 | 2019 | 25879 | 1.350 |
Why?
| | Skin | 11 | 2018 | 123 | 1.330 |
Why?
| | Mupirocin | 6 | 2019 | 14 | 1.290 |
Why?
| | beta-Lactam Resistance | 4 | 2015 | 17 | 1.220 |
Why?
| | Long-Term Care | 7 | 2017 | 53 | 1.220 |
Why?
| | Skin Care | 4 | 2018 | 15 | 1.210 |
Why?
| | Population Surveillance | 7 | 2018 | 118 | 1.210 |
Why?
| | Vancomycin | 13 | 2006 | 51 | 1.190 |
Why?
| | Microbial Sensitivity Tests | 18 | 2018 | 110 | 1.170 |
Why?
| | Disinfection | 4 | 2019 | 11 | 1.080 |
Why?
| | Enterococcus faecium | 6 | 2008 | 15 | 1.020 |
Why?
| | Bacteriological Techniques | 3 | 2017 | 20 | 1.000 |
Why?
| | Culture Media | 5 | 2017 | 37 | 0.990 |
Why?
| | Catheterization, Central Venous | 2 | 2010 | 45 | 0.940 |
Why?
| | Mass Screening | 5 | 2018 | 166 | 0.930 |
Why?
| | Hospitals | 12 | 2017 | 108 | 0.920 |
Why?
| | beta-Lactams | 2 | 2010 | 11 | 0.920 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 13 | 2014 | 41 | 0.910 |
Why?
| | Infectious Disease Transmission, Professional-to-Patient | 3 | 2010 | 6 | 0.910 |
Why?
| | Genome, Bacterial | 3 | 2017 | 13 | 0.900 |
Why?
| | Middle Aged | 45 | 2019 | 9706 | 0.900 |
Why?
| | Dengue | 3 | 2016 | 3 | 0.870 |
Why?
| | Female | 53 | 2019 | 15391 | 0.870 |
Why?
| | Escherichia coli Infections | 5 | 2018 | 33 | 0.840 |
Why?
| | Male | 50 | 2019 | 15035 | 0.820 |
Why?
| | Chicago | 18 | 2018 | 791 | 0.750 |
Why?
| | Aged | 33 | 2019 | 8582 | 0.730 |
Why?
| | Dengue Virus | 1 | 2015 | 1 | 0.720 |
Why?
| | Gram-Positive Bacteria | 2 | 2012 | 18 | 0.700 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2014 | 7 | 0.680 |
Why?
| | Virulence Factors | 1 | 2014 | 11 | 0.680 |
Why?
| | Bacterial Toxins | 1 | 2014 | 22 | 0.670 |
Why?
| | Bacterial Load | 3 | 2013 | 13 | 0.660 |
Why?
| | Acinetobacter baumannii | 1 | 2014 | 5 | 0.650 |
Why?
| | Acinetobacter Infections | 1 | 2014 | 6 | 0.650 |
Why?
| | Hand | 5 | 2008 | 50 | 0.650 |
Why?
| | Anal Canal | 1 | 2014 | 14 | 0.650 |
Why?
| | Drug Resistance, Microbial | 13 | 1999 | 100 | 0.640 |
Why?
| | Equipment Contamination | 3 | 2012 | 22 | 0.630 |
Why?
| | Methicillin Resistance | 4 | 2007 | 33 | 0.610 |
Why?
| | Community-Acquired Infections | 7 | 2014 | 68 | 0.600 |
Why?
| | Gloves, Protective | 3 | 2008 | 11 | 0.590 |
Why?
| | Critical Care | 3 | 2018 | 188 | 0.560 |
Why?
| | Staphylococcus aureus | 4 | 2019 | 82 | 0.550 |
Why?
| | Gram-Negative Bacterial Infections | 3 | 2008 | 27 | 0.530 |
Why?
| | Sensitivity and Specificity | 7 | 2015 | 574 | 0.520 |
Why?
| | Rectum | 8 | 2018 | 66 | 0.520 |
Why?
| | Adult | 29 | 2019 | 8462 | 0.510 |
Why?
| | Fomites | 1 | 2008 | 5 | 0.460 |
Why?
| | Decontamination | 1 | 2008 | 11 | 0.450 |
Why?
| | DNA, Bacterial | 7 | 2017 | 51 | 0.450 |
Why?
| | Aedes | 3 | 2017 | 3 | 0.440 |
Why?
| | Disinfectants | 3 | 2014 | 11 | 0.430 |
Why?
| | Minisatellite Repeats | 1 | 2008 | 7 | 0.430 |
Why?
| | Endemic Diseases | 1 | 2008 | 7 | 0.430 |
Why?
| | Skilled Nursing Facilities | 3 | 2018 | 14 | 0.420 |
Why?
| | Aged, 80 and over | 14 | 2018 | 4373 | 0.420 |
Why?
| | Polymerase Chain Reaction | 5 | 2016 | 203 | 0.410 |
Why?
| | Specimen Handling | 2 | 2017 | 46 | 0.400 |
Why?
| | Genes, Bacterial | 2 | 2016 | 8 | 0.400 |
Why?
| | Prevalence | 9 | 2018 | 478 | 0.400 |
Why?
| | Bacteria | 2 | 2017 | 63 | 0.390 |
Why?
| | Sequence Analysis, DNA | 4 | 2017 | 94 | 0.390 |
Why?
| | Hand Disinfection | 4 | 2010 | 18 | 0.390 |
Why?
| | Serratia marcescens | 3 | 2011 | 12 | 0.380 |
Why?
| | Gram-Negative Bacteria | 4 | 2013 | 39 | 0.380 |
Why?
| | Serratia Infections | 3 | 2011 | 11 | 0.380 |
Why?
| | Daptomycin | 1 | 2005 | 17 | 0.360 |
Why?
| | Risk Factors | 11 | 2017 | 2227 | 0.350 |
Why?
| | Asthma, Exercise-Induced | 1 | 2003 | 2 | 0.320 |
Why?
| | Nasal Cavity | 5 | 2014 | 26 | 0.320 |
Why?
| | Drug Resistance, Multiple | 2 | 2012 | 12 | 0.320 |
Why?
| | Drug Therapy, Combination | 2 | 1994 | 250 | 0.310 |
Why?
| | Disease Transmission, Infectious | 3 | 2019 | 11 | 0.310 |
Why?
| | Time Factors | 7 | 2017 | 1696 | 0.310 |
Why?
| | Pseudomonas aeruginosa | 2 | 2018 | 84 | 0.310 |
Why?
| | Practice Guidelines as Topic | 1 | 2006 | 335 | 0.310 |
Why?
| | Models, Statistical | 2 | 2015 | 136 | 0.310 |
Why?
| | Environment | 2 | 2017 | 56 | 0.300 |
Why?
| | Molecular Epidemiology | 6 | 2015 | 24 | 0.300 |
Why?
| | Case-Control Studies | 6 | 2017 | 594 | 0.280 |
Why?
| | Disease Reservoirs | 3 | 2010 | 10 | 0.260 |
Why?
| | Florida | 3 | 2016 | 17 | 0.260 |
Why?
| | Drug Contamination | 2 | 2011 | 7 | 0.260 |
Why?
| | Prisons | 2 | 2013 | 11 | 0.250 |
Why?
| | Sepsis | 2 | 2014 | 142 | 0.250 |
Why?
| | Treatment Outcome | 9 | 2018 | 3230 | 0.240 |
Why?
| | Critical Illness | 3 | 2018 | 90 | 0.240 |
Why?
| | Loiasis | 1 | 1998 | 3 | 0.220 |
Why?
| | Eye Infections, Parasitic | 1 | 1998 | 4 | 0.220 |
Why?
| | West Nile Fever | 2 | 2016 | 5 | 0.220 |
Why?
| | Environmental Microbiology | 2 | 2017 | 4 | 0.220 |
Why?
| | Temperature | 2 | 2017 | 80 | 0.220 |
Why?
| | Comorbidity | 2 | 2019 | 483 | 0.220 |
Why?
| | Disease Notification | 1 | 2018 | 4 | 0.220 |
Why?
| | Conjugation, Genetic | 2 | 1997 | 5 | 0.220 |
Why?
| | Bacterial Typing Techniques | 4 | 2011 | 13 | 0.210 |
Why?
| | Personnel, Hospital | 2 | 2008 | 15 | 0.210 |
Why?
| | Glycopeptides | 1 | 1997 | 3 | 0.200 |
Why?
| | Hospitalization | 4 | 2019 | 263 | 0.200 |
Why?
| | Thailand | 2 | 2014 | 14 | 0.200 |
Why?
| | Models, Theoretical | 1 | 2017 | 99 | 0.200 |
Why?
| | Teicoplanin | 2 | 1994 | 5 | 0.200 |
Why?
| | Selection, Genetic | 1 | 2016 | 6 | 0.200 |
Why?
| | Ciprofloxacin | 3 | 2008 | 33 | 0.190 |
Why?
| | Chromogenic Compounds | 2 | 2013 | 3 | 0.190 |
Why?
| | Feces | 1 | 2017 | 90 | 0.190 |
Why?
| | Mosquito Control | 1 | 2016 | 1 | 0.190 |
Why?
| | Financing, Government | 1 | 2016 | 14 | 0.190 |
Why?
| | Animals | 7 | 2017 | 4826 | 0.180 |
Why?
| | Candidiasis | 1 | 2015 | 14 | 0.180 |
Why?
| | Melioidosis | 1 | 2015 | 3 | 0.180 |
Why?
| | Burkholderia pseudomallei | 1 | 2015 | 3 | 0.180 |
Why?
| | Travel | 1 | 2015 | 14 | 0.180 |
Why?
| | Levofloxacin | 1 | 1995 | 4 | 0.180 |
Why?
| | Ofloxacin | 1 | 1995 | 5 | 0.180 |
Why?
| | Health Personnel | 3 | 2008 | 76 | 0.180 |
Why?
| | Models, Biological | 2 | 2014 | 417 | 0.180 |
Why?
| | Urinary Tract Infections | 1 | 2015 | 22 | 0.180 |
Why?
| | Markov Chains | 1 | 2015 | 31 | 0.180 |
Why?
| | Rain | 1 | 2015 | 1 | 0.180 |
Why?
| | West Nile virus | 1 | 2015 | 2 | 0.180 |
Why?
| | Monte Carlo Method | 1 | 2015 | 54 | 0.180 |
Why?
| | Nontuberculous Mycobacteria | 1 | 2015 | 6 | 0.170 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2015 | 8 | 0.170 |
Why?
| | Water Microbiology | 1 | 2015 | 10 | 0.170 |
Why?
| | Soaps | 3 | 2010 | 10 | 0.170 |
Why?
| | Adolescent | 9 | 2018 | 2314 | 0.170 |
Why?
| | Biomedical Research | 1 | 2016 | 78 | 0.170 |
Why?
| | Hospitals, University | 1 | 2015 | 47 | 0.170 |
Why?
| | Patient Care | 2 | 2013 | 30 | 0.170 |
Why?
| | Data Collection | 1 | 2015 | 121 | 0.170 |
Why?
| | Pharynx | 1 | 2014 | 10 | 0.170 |
Why?
| | Cost Savings | 1 | 2014 | 33 | 0.170 |
Why?
| | Medical Staff, Hospital | 1 | 2014 | 18 | 0.160 |
Why?
| | Mandatory Reporting | 1 | 2013 | 5 | 0.160 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2013 | 5 | 0.160 |
Why?
| | Colorimetry | 1 | 2013 | 1 | 0.160 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2013 | 12 | 0.160 |
Why?
| | Multivariate Analysis | 4 | 2013 | 354 | 0.150 |
Why?
| | Air Microbiology | 1 | 2013 | 3 | 0.150 |
Why?
| | Aerosols | 1 | 2013 | 14 | 0.150 |
Why?
| | Fungi | 1 | 2013 | 7 | 0.150 |
Why?
| | Poisson Distribution | 2 | 2010 | 26 | 0.150 |
Why?
| | United States | 6 | 2017 | 2012 | 0.150 |
Why?
| | Cohort Studies | 2 | 2012 | 1573 | 0.150 |
Why?
| | Catheter-Related Infections | 1 | 2012 | 22 | 0.140 |
Why?
| | Attitude of Health Personnel | 1 | 2014 | 162 | 0.140 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 56 | 0.140 |
Why?
| | Epidemiologic Methods | 1 | 2012 | 24 | 0.140 |
Why?
| | Quality of Health Care | 1 | 2013 | 119 | 0.140 |
Why?
| | Hospital Administration | 2 | 2014 | 15 | 0.140 |
Why?
| | Patient Transfer | 1 | 2012 | 22 | 0.140 |
Why?
| | Illinois | 4 | 2018 | 216 | 0.140 |
Why?
| | Hospitals, Teaching | 4 | 2010 | 34 | 0.130 |
Why?
| | Cluster Analysis | 3 | 2018 | 56 | 0.130 |
Why?
| | Staphylococcal Skin Infections | 2 | 2007 | 14 | 0.130 |
Why?
| | Enterococcus faecalis | 2 | 2002 | 8 | 0.120 |
Why?
| | Soft Tissue Infections | 2 | 2007 | 24 | 0.120 |
Why?
| | Multilocus Sequence Typing | 3 | 2016 | 10 | 0.120 |
Why?
| | Blood | 1 | 2009 | 26 | 0.120 |
Why?
| | Administration, Intranasal | 2 | 2019 | 22 | 0.120 |
Why?
| | Infant | 3 | 2016 | 574 | 0.110 |
Why?
| | Prospective Studies | 5 | 2012 | 1534 | 0.110 |
Why?
| | Academic Medical Centers | 1 | 2009 | 133 | 0.110 |
Why?
| | Severe Dengue | 1 | 2008 | 1 | 0.110 |
Why?
| | Imipenem | 1 | 2008 | 7 | 0.110 |
Why?
| | Pseudomonas Infections | 1 | 2008 | 59 | 0.100 |
Why?
| | Public Housing | 1 | 2007 | 5 | 0.100 |
Why?
| | Catheterization | 1 | 2007 | 61 | 0.100 |
Why?
| | Indicators and Reagents | 1 | 2007 | 20 | 0.100 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2007 | 19 | 0.100 |
Why?
| | Simplexvirus | 1 | 2006 | 11 | 0.100 |
Why?
| | Hepatitis | 1 | 2006 | 9 | 0.100 |
Why?
| | DNA, Viral | 1 | 2007 | 106 | 0.100 |
Why?
| | Syringes | 3 | 2011 | 12 | 0.100 |
Why?
| | Bone Marrow Transplantation | 1 | 2006 | 43 | 0.100 |
Why?
| | Immunosuppression | 1 | 2006 | 38 | 0.100 |
Why?
| | Cytomegalovirus | 1 | 2007 | 80 | 0.100 |
Why?
| | Colony Count, Microbial | 3 | 2015 | 22 | 0.100 |
Why?
| | Viral Load | 1 | 2007 | 190 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2007 | 79 | 0.090 |
Why?
| | Program Evaluation | 1 | 2007 | 139 | 0.090 |
Why?
| | Geography | 2 | 2017 | 19 | 0.090 |
Why?
| | Culex | 2 | 2016 | 3 | 0.090 |
Why?
| | Osteomyelitis | 1 | 2005 | 23 | 0.090 |
Why?
| | HIV Infections | 1 | 2013 | 806 | 0.090 |
Why?
| | Retrospective Studies | 2 | 2018 | 2619 | 0.090 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 1997 | 46 | 0.090 |
Why?
| | Lumbosacral Region | 1 | 2005 | 47 | 0.090 |
Why?
| | Phylogeny | 2 | 2015 | 77 | 0.090 |
Why?
| | Child | 4 | 2016 | 1338 | 0.090 |
Why?
| | Ampicillin | 2 | 1995 | 9 | 0.090 |
Why?
| | Treatment Failure | 1 | 2005 | 160 | 0.090 |
Why?
| | Kidney Transplantation | 1 | 2006 | 122 | 0.080 |
Why?
| | Ascomycota | 1 | 2004 | 2 | 0.080 |
Why?
| | Mitosporic Fungi | 1 | 2004 | 2 | 0.080 |
Why?
| | Fungemia | 1 | 2004 | 4 | 0.080 |
Why?
| | Drug Synergism | 2 | 1994 | 65 | 0.080 |
Why?
| | Young Adult | 3 | 2018 | 1818 | 0.080 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2004 | 12 | 0.080 |
Why?
| | Infant, Newborn | 3 | 2016 | 630 | 0.080 |
Why?
| | Mycoses | 1 | 2004 | 20 | 0.080 |
Why?
| | Aminoglycosides | 2 | 2013 | 12 | 0.080 |
Why?
| | Membrane Transport Proteins | 2 | 2014 | 43 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2004 | 96 | 0.080 |
Why?
| | Hemolysin Proteins | 1 | 2002 | 2 | 0.070 |
Why?
| | Gelatinases | 1 | 2002 | 4 | 0.070 |
Why?
| | Mexico | 2 | 2015 | 18 | 0.070 |
Why?
| | Nurse's Role | 1 | 2003 | 133 | 0.070 |
Why?
| | Mathematics | 1 | 2000 | 34 | 0.070 |
Why?
| | Heparin | 2 | 2011 | 35 | 0.060 |
Why?
| | Cephalosporins | 2 | 1998 | 18 | 0.060 |
Why?
| | Child, Preschool | 2 | 2016 | 726 | 0.060 |
Why?
| | Lumbar Vertebrae | 1 | 2005 | 390 | 0.060 |
Why?
| | Sodium Chloride | 2 | 2011 | 42 | 0.060 |
Why?
| | Statistics as Topic | 2 | 2015 | 125 | 0.060 |
Why?
| | Plasmids | 2 | 2016 | 49 | 0.060 |
Why?
| | Carbon-Oxygen Ligases | 1 | 1999 | 2 | 0.060 |
Why?
| | Hygiene | 1 | 2019 | 15 | 0.060 |
Why?
| | Confidence Intervals | 2 | 2012 | 104 | 0.060 |
Why?
| | Integrons | 1 | 2018 | 2 | 0.060 |
Why?
| | Incidence | 2 | 2015 | 699 | 0.060 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 48 | 0.050 |
Why?
| | Genotype | 1 | 1999 | 384 | 0.050 |
Why?
| | Chromosomes, Bacterial | 1 | 1997 | 2 | 0.050 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 1997 | 10 | 0.050 |
Why?
| | Surgical Wound Infection | 1 | 1999 | 98 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 46 | 0.050 |
Why?
| | Patient Education as Topic | 1 | 2019 | 181 | 0.050 |
Why?
| | Gloves, Surgical | 1 | 1996 | 2 | 0.050 |
Why?
| | Protective Clothing | 1 | 1996 | 6 | 0.050 |
Why?
| | Ceftazidime | 1 | 1996 | 13 | 0.050 |
Why?
| | Length of Stay | 2 | 2014 | 300 | 0.050 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 52 | 0.050 |
Why?
| | Arizona | 1 | 2016 | 3 | 0.050 |
Why?
| | Outcome Assessment (Health Care) | 1 | 2019 | 276 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2016 | 76 | 0.050 |
Why?
| | Respiration, Artificial | 2 | 2012 | 86 | 0.050 |
Why?
| | Bacteriuria | 1 | 2015 | 5 | 0.050 |
Why?
| | Candida | 1 | 2015 | 12 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2017 | 362 | 0.050 |
Why?
| | Costs and Cost Analysis | 1 | 2016 | 36 | 0.050 |
Why?
| | Borrelia burgdorferi Group | 1 | 1995 | 6 | 0.050 |
Why?
| | Ticks | 1 | 1995 | 5 | 0.050 |
Why?
| | Penicillins | 1 | 1995 | 11 | 0.050 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2015 | 13 | 0.040 |
Why?
| | Genomics | 1 | 2015 | 22 | 0.040 |
Why?
| | Insect Vectors | 1 | 2015 | 2 | 0.040 |
Why?
| | Climate | 1 | 2015 | 4 | 0.040 |
Why?
| | Gastric Juice | 1 | 2015 | 4 | 0.040 |
Why?
| | Drinking Water | 1 | 2015 | 5 | 0.040 |
Why?
| | Sputum | 1 | 2015 | 23 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2015 | 20 | 0.040 |
Why?
| | Anti-Infective Agents | 1 | 1995 | 58 | 0.040 |
Why?
| | Seasons | 1 | 2015 | 36 | 0.040 |
Why?
| | Public Health | 1 | 2015 | 47 | 0.040 |
Why?
| | Drugs, Investigational | 1 | 1994 | 10 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 1999 | 1149 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2016 | 320 | 0.040 |
Why?
| | Gentamicins | 1 | 1994 | 15 | 0.040 |
Why?
| | Genetic Markers | 1 | 2014 | 49 | 0.040 |
Why?
| | Organizational Culture | 1 | 2014 | 19 | 0.040 |
Why?
| | Campylobacter Infections | 1 | 2014 | 12 | 0.040 |
Why?
| | Diffusion | 1 | 2014 | 31 | 0.040 |
Why?
| | Reimbursement, Incentive | 1 | 2013 | 6 | 0.040 |
Why?
| | Species Specificity | 1 | 2014 | 76 | 0.040 |
Why?
| | Sex Factors | 1 | 2015 | 447 | 0.040 |
Why?
| | Focus Groups | 1 | 2014 | 78 | 0.040 |
Why?
| | Longevity | 1 | 2014 | 32 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2014 | 72 | 0.040 |
Why?
| | Communicable Disease Control | 1 | 2013 | 9 | 0.040 |
Why?
| | Colistin | 1 | 2013 | 4 | 0.040 |
Why?
| | Chickens | 1 | 2014 | 52 | 0.040 |
Why?
| | Hospitals, Public | 2 | 2007 | 30 | 0.040 |
Why?
| | Minocycline | 1 | 2013 | 8 | 0.040 |
Why?
| | Qualitative Research | 1 | 2014 | 95 | 0.040 |
Why?
| | Epidemiological Monitoring | 1 | 2013 | 7 | 0.040 |
Why?
| | Hospital Costs | 1 | 2014 | 66 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2013 | 7 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2019 | 1784 | 0.040 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 170 | 0.040 |
Why?
| | Phenotype | 1 | 2014 | 319 | 0.040 |
Why?
| | Ventilation | 1 | 2013 | 3 | 0.040 |
Why?
| | Nose | 1 | 2013 | 25 | 0.040 |
Why?
| | Propensity Score | 1 | 2012 | 47 | 0.040 |
Why?
| | Nursing Homes | 1 | 2012 | 32 | 0.040 |
Why?
| | Agar | 1 | 2012 | 1 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2007 | 322 | 0.040 |
Why?
| | Contact Tracing | 1 | 2011 | 6 | 0.030 |
Why?
| | Indiana | 1 | 2011 | 17 | 0.030 |
Why?
| | Odds Ratio | 1 | 2012 | 285 | 0.030 |
Why?
| | Serratia | 1 | 2010 | 7 | 0.030 |
Why?
| | APACHE | 2 | 2001 | 29 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2010 | 128 | 0.030 |
Why?
| | Patient Isolation | 1 | 2010 | 23 | 0.030 |
Why?
| | Drug and Narcotic Control | 1 | 2009 | 8 | 0.030 |
Why?
| | Isotonic Solutions | 1 | 2009 | 17 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2012 | 772 | 0.030 |
Why?
| | Quality Control | 1 | 2009 | 47 | 0.030 |
Why?
| | Safety | 1 | 2009 | 54 | 0.030 |
Why?
| | Drug Industry | 1 | 2009 | 28 | 0.030 |
Why?
| | China | 1 | 2009 | 114 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2009 | 70 | 0.030 |
Why?
| | Texas | 1 | 2008 | 10 | 0.030 |
Why?
| | Seroepidemiologic Studies | 1 | 2008 | 19 | 0.030 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2008 | 11 | 0.030 |
Why?
| | Neural Tube Defects | 1 | 2008 | 10 | 0.030 |
Why?
| | Porins | 1 | 2008 | 23 | 0.030 |
Why?
| | Bedding and Linens | 1 | 2007 | 5 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2007 | 68 | 0.030 |
Why?
| | Methicillin | 1 | 2007 | 4 | 0.030 |
Why?
| | Blotting, Western | 1 | 2008 | 228 | 0.030 |
Why?
| | Gram-Positive Cocci | 1 | 2007 | 5 | 0.030 |
Why?
| | Alcohols | 1 | 2007 | 9 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 47 | 0.020 |
Why?
| | Environmental Monitoring | 1 | 2006 | 9 | 0.020 |
Why?
| | Patients | 1 | 2006 | 20 | 0.020 |
Why?
| | Cytomegalovirus Infections | 1 | 2007 | 80 | 0.020 |
Why?
| | Asphyxia Neonatorum | 1 | 1984 | 1 | 0.020 |
Why?
| | Animals, Newborn | 1 | 1984 | 74 | 0.020 |
Why?
| | Probability | 1 | 2004 | 94 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2007 | 761 | 0.020 |
Why?
| | Blood Glucose | 1 | 1984 | 111 | 0.020 |
Why?
| | Survival Analysis | 1 | 2004 | 364 | 0.020 |
Why?
| | Virulence | 1 | 2002 | 12 | 0.020 |
Why?
| | Drug Resistance | 1 | 2002 | 63 | 0.020 |
Why?
| | Mortality | 1 | 2002 | 63 | 0.020 |
Why?
| | Prognosis | 1 | 2004 | 858 | 0.020 |
Why?
| | Risk Assessment | 1 | 2004 | 688 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2004 | 1117 | 0.010 |
Why?
| | Hospital Bed Capacity, 500 and over | 1 | 1998 | 10 | 0.010 |
Why?
| | Surgical Procedures, Operative | 1 | 1999 | 32 | 0.010 |
Why?
| | Enteral Nutrition | 1 | 1998 | 50 | 0.010 |
Why?
| | Risk | 1 | 1998 | 208 | 0.010 |
Why?
| | Genetic Variation | 1 | 1998 | 109 | 0.010 |
Why?
| | Digestive System | 1 | 1996 | 19 | 0.010 |
Why?
| | Sequence Analysis | 1 | 1995 | 4 | 0.010 |
Why?
| | Sequence Alignment | 1 | 1995 | 31 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1995 | 258 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1995 | 319 | 0.010 |
Why?
| | Glucagon | 1 | 1984 | 3 | 0.010 |
Why?
| | Pyruvates | 1 | 1984 | 3 | 0.010 |
Why?
| | Lactates | 1 | 1984 | 8 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 1984 | 47 | 0.010 |
Why?
| | Glycogen | 1 | 1984 | 9 | 0.010 |
Why?
| | Catecholamines | 1 | 1984 | 16 | 0.010 |
Why?
| | Insulin | 1 | 1984 | 90 | 0.010 |
Why?
| | Liver | 1 | 1984 | 201 | 0.000 |
Why?
| | Rats | 1 | 1984 | 943 | 0.000 |
Why?
|
|
Hayden's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|